Data on Maternal Age and Successful Egg Freezing With Preimplantation Genetic Screening (PGS) Presented at American Society for Reproductive Medicine Meeting

LIVINGSTON, NJ and HONOLULU, HI--(Marketwired - Oct 22, 2014) - Reprogenetics, the largest genetics laboratory specializing in Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD) in the U.S., announces data being presented from two studies at the annual American Society for Reproductive Medicine (ASRM) meeting taking place this week in Honolulu. One study quantifies the sharp decline in the number of normal oocytes (eggs) available for successful in vitro fertilization (IVF) as a woman's age increases. The second study evaluates the effect of PGS on pregnancy rates in frozen donor egg embryo transfer cycles. These studies are among more than 20 oral presentations and poster sessions selected for inclusion by conference organizers presented by the company and its partners throughout the meeting.

"There is a great benefit to freezing eggs prior to reaching advanced maternal age when the number of chromosomal abnormalities will begin to increase," said Santiago Munné, Ph.D., Founder and Director of Reprogenetics. "Preimplantation Genetic Screening can help identify optimal embryos to achieve positive pregnancy outcomes."

Data was presented showing that the number of stimulation cycles required to produce enough oocytes needed to yield a single normal embryo increases significantly after the age of 37, and even more so after the age of 42. Researchers concluded that women considering egg cryopreservation (freezing) should be advised of the increase in challenges with fertility preservation with advancing age so that they may consider options that will allow them the greatest opportunity for success.

An additional study to be presented today will compare the outcomes in first time egg donor recipient cycles of fresh embryo transfers compared to frozen egg transfers with or without PGS.

ASRM has also honored Dr. Munné with its Star Award for the fourth consecutive year, which is given to individuals who have presented during the meeting at least nine times -- 2004-2014. The acknowledgement reflects his and the Company's ongoing investment in research and collaborations to advance the field of reproductive genetics.

"This annual meeting brings together the brightest minds to share advancements in the fast-evolving field of reproductive medicine," Munné continued. "This week's presentations reflect Reprogenetics' continued commitment as part of this community to developing better fertility solutions for patients worldwide."

About Reprogenetics
Reprogenetics is the largest genetics laboratory in the U.S. specializing in preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD), with over 41,000 performed procedures and hundreds of publications. Dr. Santiago Munné and Dr. Jacques Cohen founded Reprogenetics in 2000 after extensive experience in PGD and IVF. Reprogenetics offers a comprehensive and personalized service to its referring IVF centers and their patients. Genetic counselors are intricately involved in the process and interact routinely with patients pursuing all diagnostic tests and services to improve pregnancy outcomes. Reprogenetics has locations all over the world including in the USA, Spain, UK, Japan, Peru and South America.